Actively Recruiting
Phase 2 Study of Pioglitazone with Tyrosine Kinase Inhibitors in Adults with Chronic Myeloid Leukemia After Unsuccessful First TKI Discontinuation to Prepare for a Second Treatment Stop
Led by Versailles Hospital · Updated on 2026-07-06
26
Participants Needed
6
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and pharmacokinetics of combining Pioglitazone PIO with Tyrosine Kinase Inhibitors TKIs in adults with Chronic Myeloid Leukemia CML who have lost their major molecular response MMR after stopping TKI treatment once. The study also aims to assess survival without losing MMR over 12 months after a second TKI discontinuation in participants who achieve or maintain a deep molecular response less than MR4.5 after receiving the combination therapy for at least six months. Participants receive a combination of Pioglitazone and a TKI drug, having been treated previously with imatinib, dasatinib, nilotinib, or bosutinib. The combination is administered for at least six months before a second attempt to stop TKI treatment is made. The study is a single-group, phase II trial conducted at one center, focusing on the treatment of CML following molecular response loss. During the study, participants undergo regular visits and assessments to monitor safety and drug levels, including adverse events tracked up to 24 months after enrollment. The primary outcomes include the number of treatment-related side effects and treatment-free survival following discontinuation of Pioglitazone and TKIs. Participants are also monitored for liver function and other health indicators, with the total study duration extending up to two years after inclusion.
CONDITIONS
Brief Title
Second STOP After Pioglitazone Priming in CML Patients
Research Team
S
Sandrine Roux, MC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here